Curaleaf Holdings Inc
CURA: XTSE (CAN)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
CAD 28.20 | Wpxp | Xnkxzyvq |
Robust Q2 Shows Why Curaleaf’s Stock Has Fallen Less than Peers, but Stock Remains Very Undervalued
Any inflationary cost pressure seems to be in Curaleaf’s rearview mirror, as second-quarter revenue grew 8% sequentially to $338 million and adjusted EBITDA margin expanded 220 basis points to 25.6%. In comparison, first-quarter revenue declined 2% sequentially and adjusted EBITDA margin contracted 150 basis points.